This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is J&J's Pharma Sales Slowdown a Warning for Other Players?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.
After Johnson & Johnson Earnings, Buy These Pharma Stocks
by Ryan McQueeney
Shares of Johnson & Johnson (JNJ) slid nearly 3.5% in morning trading Tuesday after the pharma giant's first-quarter earnings results were met with mixed reactions from investors. As the sell-off continues, investors focused on large-cap pharma companies may want to move their money into stronger options this earnings season.
Did Pharma & Biotech M&As Pick Pace in Q1?
by Arpita Dutt
Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.
5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now
by Zacks Equity Research
Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.
Geron Stock Rises after Positive Interim Update on Imetelstat
by Zacks Equity Research
Shares of Geron Corporation (GERN) increased almost 20% on Monday after it provided a positive update on two late-stage studies for imetelstat, its lead pipeline candidate.
Forget Novartis, Buy These Two Pharma Stocks Instead
by Arpita Dutt
With Novartis (NVS) being a Zacks Rank #4 (Sell) stock, here is a look at two European pharma stocks that sport a strong Zacks Rank.
Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk
by Zacks Equity Research
A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control
Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?
by Arpita Dutt
Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.
Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).
VIVUS to Regain Commercial Rights for Stendra from Sanofi
by Zacks Equity Research
VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
by Arpita Dutt
This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.
Flexion (FLXN) Stock Soars 35% on $1 Billion Sanofi Buyout
by Joseph Lu
Shares of Flexion Therapeutics (FLXN) soared on Thursday, up 36% to $26.80 per share following reports that French drug giant Sanofi (SNY) is in talks to purchase the biotech company for more than $1 billion in cash.
Merck Closes Acquisition of Controlling Stake in Vallee S.A
by Zacks Equity Research
Merck & Co., Inc. (MRK) has completed the previously announced acquisition of a controlling stake in Vallee S.A., a leading privately held producer of animal health products in Brazil.
Will Sanofi (SNY) Prove to be a Suitable Value Stock?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop
by Zacks Equity Research
Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.
What are Sanofi's (SNY) Strengths and Challenges in 2017?
by Zacks Equity Research
We issued an updated research report on Sanofi (SNY) on Mar 16, 2017.
Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat
by Zacks Equity Research
We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.
Amgen's Repatha Meets Primary Endpoint in Phase III Study
by Zacks Equity Research
Amgen, Inc. (AMGN) announced positive data from a phase III study evaluating Repatha in patients who were receiving apheresis to help control their low-density lipoprotein cholesterol (LDL-C).
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays
by Zacks Equity Research
We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.
Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?
by Zacks Equity Research
Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.
Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates
by Zacks Equity Research
Immune Design Corp.(IMDZ) reported fourth-quarter 2016 loss of 57 cents per share, in line with Zacks Consensus Estimate but narrower than the year-ago loss of 60 cents.
Ionis Pharma Lipid Disorder Candidate Positive in Phase III
by Zacks Equity Research
Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.
Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.
5 FDA Decisions to Watch Out for in Mar 2017
by Arpita Dutt
Companies like Merck (MRK) are awaiting key FDA decisions this month.
Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug
by Arpita Dutt
Quite a few companies including AstraZeneca (AZN) provided pipeline/regulatory updates this week.